Chronic Rhinosinusitis Without Nasal Polyps Epidemiology Forecast Insight

DelveInsight’s ‘Chronic Rhinosinusitis without Nasal Polyps–Epidemiology Forecast—2030’ report delivers an in-depth understanding of Chronic Rhinosinusitis without Nasal Polyps, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Chronic Rhinosinusitis without Nasal Polyps Disease Understanding

Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is more prevalent than Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). Certain diseases including allergic and non-allergic upper and lower airway diseases, epithelial cell disorders, immunodeficiency’s, autoimmune diseases, and some infectious diseases predispose to the phenotype Chronic Rhinosinusitis without Nasal Polyps (CRSsNP). Additionally, environmental and host factors, examples of which include smoking, a higher incidence of abnormal biofilms, and innate immune defects play a role in the pathogenesis of this disease. Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is characterized by histologic abnormalities, including basement membrane thickening (fibrosis) and goblet cell hyperplasia. Neutrophils and several chemokine’s, TGF-β and CXCL-8, play a role in Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) remodeling. However, some researchers have published conflicting data on whether the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) endotypes is characterized by neutrophilia or eosinophilia or both. Therefore, there is an unmet need of additional studies to better elucidate the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)  mechanism, endotypes, and evidence based treatment strategies; and ultimately poses as a challenge to understand the global burden of disease (Cho et al., 2016).

 

The total prevalence of Chronic Rhinosinusitis (CRS) cases including both the phenotypes (Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is estimated to be 15.5% in the USA and 10.9% in the EU. Limited studies have been published on the prevalence and immunologic characteristics of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in Asian patients, however, most of the published literatures record the prevalence of the total Chronic Rhinosinusitis (CRS) at 7% in Japan (Slovick et al., 2014).

 

In an article recently published in The Journal of Allergy and Clinical Immunology: In Practice, Benjamin et al sought to perform a comprehensive phenotypic characterization of subjects with Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in an academic clinic setting, using patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) as a comparator. The researchers found that out of all patients identified to have Chronic Rhinosinusitis (CRS), approximately 80% had Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) and approximately 20% had Chronic Rhinosinusitis with Nasal Polyps (CRSwNP). The Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) phenotype is more common in female subjects at 60%. The incidents of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) are observed to increase with age reaching a plateau after 60 years  (Slovick et al., 2014).

 

Further, in depth literature analysis suggest that Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is clinically manifested with various comorbidities including allergies such as allergic rhinitis, food allergies, contact allergies, and drug hypersensitivity. Other comorbidities include asthma, COPD, eczema and urticaria. The prevalence of comorbidities was observed more than one in a patient. Almost 20% of patients with Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) were clinically presented with asthma, whereas 49.5% of the patients were reported to being atopic (Khan et al., 2019).

 

These studies and corresponding parameters have been considered while forecasting the epidemiology of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) and its sub-segments during the study period [2018–2030]. Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) is a growing health concern as it significantly impacts the quality of life. The increase in prevalence is observed in the western and developing countries. More robust studies investigating Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) prevalence and immunology, are necessary to understand the extent of the Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) problem and identify preventive strategies to cope with the potential population surge in the future.

Chronic Rhinosinusitis without Nasal Polyps Epidemiology

The Chronic Rhinosinusitis without Nasal Polyps epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

 

Key Findings

The disease epidemiology covered in the report provides historical as well as forecasted Chronic Rhinosinusitis without Nasal Polyps epidemiology segmented as the Total Chronic Rhinosinusitis (CRS) Prevalent cases, Total Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Prevalent cases, Gender-Specific Prevalent cases of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP), Prevalence of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) on the basis of comorbidities. The report includes the prevalent scenario of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

Country Wise- Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Epidemiology

The epidemiology segment also provides the Chronic Rhinosinusitis without Nasal Polyps epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

  • The total prevalent population of Chronic Rhinosinusitis without Nasal Polyps associated in 7MM countries was estimated to be 60,792,290 cases in 2020 and expected to increase at a CAGR of 0.45% for the study period, i.e., 2018–2030.
  • As per the estimates, United States has the highest prevalent population of Chronic Rhinosinusitis without Nasal Polyps in 7MM.
  • Among the EU5 countries, Germany had the highest prevalent population of Chronic Rhinosinusitis without Nasal Polyps. On the other hand, Spain had the lowest number of cases, 40,687,140 cases in 2020.

Scope of the Report

  • Chronic Rhinosinusitis without Nasal Polyps report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns
  • Chronic Rhinosinusitis without Nasal Polyps Epidemiology Report and Model provide an overview of the risk factors and global trends of Chronic Rhinosinusitis without Nasal Polyps in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight into the historical and forecasted patient pool of Chronic Rhinosinusitis without Nasal Polyps in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps recognize the growth opportunities in the 7MM concerning the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Chronic Rhinosinusitis without Nasal Polyps
  • The report provides the segmentation of the Chronic Rhinosinusitis without Nasal Polyps epidemiology by prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps in 7MM
  • The report provides the segmentation of the Chronic Rhinosinusitis without Nasal Polyps epidemiology by Prevalence of Chronic Rhinosinusitis without Nasal Polyps, Prevalence of Chronic Rhinosinusitis based on comorbidities, gender-specific cases of Chronic Rhinosinusitis without Nasal Polyps in 7MM

Report Highlights

  • 10-year Forecast of Chronic Rhinosinusitis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps
  • Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities
  • Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

KOL Views

We interview KOLs, and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM concerning the patient population about Chronic Rhinosinusitis without Nasal Polyps?
  • What are the key Findings of Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021–2030)?
  • What would be the total number of patients with Chronic Rhinosinusitis without Nasal Polyps across the 7MM during the forecast period (2021–2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021–2030)?
  • At what CAGR the patient population is expected to grow by 7MM during the forecast period (2021–2030)?
  • What are the disease risk, burden, and unmet needs of Chronic Rhinosinusitis without Nasal Polyps?
  • What are the currently available treatments for Chronic Rhinosinusitis without Nasal Polyps?

Reasons to buy

The Chronic Rhinosinusitis without Nasal Polyps (CRSsNP) Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Chronic Rhinosinusitis without Nasal Polyps market
  • Quantify patient populations in the global Chronic Rhinosinusitis without Nasal Polyps market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and gender that present the best opportunities for Chronic Rhinosinusitis without Nasal Polyps therapeutics in each of the markets covered
  • Understand the magnitude of Chronic Rhinosinusitis without Nasal Polyps population by its prevalent cases
  • Understand the magnitude of Chronic Rhinosinusitis without Nasal Polyps population by its clinical manifestation specific cases
  • The Chronic Rhinosinusitis without Nasal Polyps epidemiology report and model was written and developed by Masters and PhD level epidemiologists
  • The Chronic Rhinosinusitis without Nasal Polyps Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Chronic Rhinosinusitis without Nasal Polyps Market Overview at a Glance

3. Market Share (%) Distribution of Chronic Rhinosinusitis without Nasal Polyps in 2018

4. Market Share (%) Distribution of Chronic Rhinosinusitis without Nasal Polyps  in 2030

5. Executive summary

6. Organizations

7. Disease Background and Overview

7.1. Introduction

7.2. Classification

7.3. Causes

7.4. Symptoms and Complications

7.5. Pathophysiology

7.6. Diagnosis

8. Epidemiology and Patient Population

9. Key Findings

10. Total Diagnosed Prevalent Population of Chronic Rhinosinusitis without Nasal Polyps

11. Country Wise-Epidemiology of Chronic Rhinosinusitis without Nasal Polyps

12. The United States

12.1. Assumptions and Rationale

12.1.1. Total Prevalence of Chronic Rhinosinusitis in the United States

12.1.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United States

12.1.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the United States

12.1.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13. EU5 Countries

13.1. Germany

13.1.1. Total Prevalence of Chronic Rhinosinusitis in Germany

13.1.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany

13.1.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany

13.1.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.2. France

13.2.1. Total Prevalence of Chronic Rhinosinusitis in France

13.2.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France

13.2.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France

13.2.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.3. Italy

13.3.1. Total Prevalence of Chronic Rhinosinusitis in Italy

13.3.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy

13.3.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy

13.3.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.4. Spain

13.4.1. Total Prevalence of Chronic Rhinosinusitis in Spain

13.4.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Spain

13.4.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Spain

13.4.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.5. The United Kingdom

13.5.1. Total Prevalence of Chronic Rhinosinusitis in the UK

13.5.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in  the UK

13.5.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in the UK

13.5.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

13.6. Japan

13.6.1. Total Prevalence of Chronic Rhinosinusitis in Japan

13.6.2. Total Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan

13.6.3. Gender-specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan

13.6.4. Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on comorbidities

14. Treatment Goals

15. Patient Journey for Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

16. Unmet Needs

17. Appendix

18. Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

List of Table

Table 1: Summary of Chronic Rhinosinusitis without Nasal polyps, Market, Epidemiology, and Key Events (2018–2030)

Table 2: Organizations contributing towards the fight against Chronic Rhinosinusitis without Nasal Polyps (CRSsNP)

Table 3: Total Prevalent Patient Population of Chronic Rhinosinusitis without Nasal Polyps in 7MM (2018–2030)

Table 4: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in the United States (2018–2030)

Table 5: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in the United States (2018–2030)

Table 6: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in United States (2018–2030)

Table 7: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in the United States (2018–2030)

Table 8: Total Prevalent Cases of Chronic Rhinosinusitis in Germany (2018–2030)

Table 9: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Germany (2018–2030)

Table 10: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany (2018–2030)

Table 11: Sub-type Specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany (2018–2030)

Table 12: Total Prevalent Cases of Chronic Rhinosinusitis in France (2018–2030)

Table 13: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in France (2018–2030)

Table 14: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France (2018–2030)

Table 15: Sub-type Specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France (2018–2030)

Table 16: Total Prevalent Cases of Chronic Rhinosinusitis in Italy (2018–2030)

Table 17: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Italy (2018–2030)

Table 18: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy (2018–2030)

Table 19: Sub-type Specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy (2018–2030)

Table 20: Total Prevalent Cases of Chronic rhino sinusitis in Spain (2018–2030)

List of Figures

Figure 1: Schematic depiction of pathological mechanisms of chronic rhinosinusitis without nasal polyps.

Figure 2: Chronic rhinosinusitis without nasal polyps.: T Cell Biology

Figure 3: Risk factors for the development of CRS

Figure 4: Total Prevalent Population of Chronic Rhinosinusitis without Nasal Polyps in 7MM in 1000’s (2018–2030)

Figure 6: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in the United States (2018–2030)

Figure 7: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in the United States (2018–2030)

Figure 8: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in United States (2018–2030)

Figure 9: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in the United States (2018–2030)

Figure 10: Total Prevalent Cases of Chronic Rhinosinusitis in Germany (2018–2030)

Figure 11: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Germany (2018–2030)

Figure 12: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Germany (2018–2030)

Figure 13: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Germany (2018–2030)

Figure 14: Total Prevalent Cases of Chronic Rhinosinusitis in France (2018–2030)

Figure 15: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in France (2018–2030)

Figure 16: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in France (2018–2030)

Figure 17: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in France (2018–2030)

Figure 18: Total Prevalent Cases of Chronic Rhinosinusitis in Italy (2018–2030)

Figure 19: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Italy (2018–2030)

Figure 20: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Italy (2018–2030)

Figure 21: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Italy (2018–2030)

Figure 22: Total Prevalent Cases of Chronic Rhinosinusitis in Spain (2018–2030)

Figure 23: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Spain (2018–2030)

Figure 24: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Spain (2018–2030)

Figure 25: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Spain (2018–2030)

Figure 26: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in United Kingdom (2018–2030)

Figure 27: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in United Kingdom (2018–2030)

Figure 28: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in United Kingdom (2018–2030)

Figure 29: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in United   Kingdom (2018–2030)

Figure 30: Total Prevalent Cases of Chronic Rhinosinusitis (CRS) in Japan (2018–2030)

Figure 31: Total Prevalent Cases of Chronic Rhinosinusitis without Nasal Polyps based on Severity in Japan (2018–2030)

Figure 32: Gender specific Prevalence of Chronic Rhinosinusitis without Nasal Polyps in Japan (2018–2030)

Figure 33: Prevalence of Chronic Rhinosinusitis without Nasal Polyps based on Comorbidities in Japan (2018–2030)

Figure 34: 7 Major Market Size of Chronic Rhinosinusitis without Nasal Polyps in USD Million (2018–2030)

Figure 35: 7 Major Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 36: Total Market Size of Chronic Rhinosinusitis without Nasal Polyps in the United States, USD Million (2018–2030)

Figure 37: The United States Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 38: Total Market Size of Chronic Rhinosinusitis without Nasal Polyps in Germany, USD Million (2018–2030)

Figure 39: The Germany Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 40: Market Size of Chronic Rhinosinusitis without Nasal Polyps in France, USD Million (2018–2030)

Figure 41: The France Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 42: Market Size of Chronic Rhinosinusitis without Nasal Polyps in Italy, USD Million (2018–2030)

Figure 43: The Italy Market Size of Chronic rhinosinusitis without nasal polyps by Therapies in USD Million (2018–2030)

Figure 44: Market Size of Chronic Rhinosinusitis without Nasal Polyps in Spain, USD Million (2018–2030)

Figure 45: The Spain Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 46: Market Size of Chronic Rhinosinusitis without Nasal Polyps in United Kingdom, USD Million (2018–2030)

Figure 47: The United Kingdom Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Figure 48: Market Size of Chronic Rhinosinusitis without Nasal Polyps in Japan, USD Million (2018–2030)

Figure 49: The Japan Market Size of Chronic Rhinosinusitis without Nasal Polyps by Therapies in USD Million (2018–2030)

Forward to Friend

Need A Quote